Case Report

Rapid aneurysm growth and rupture in systemic lupus erythematosus

Christopher S. Graffeo, Omar Tanweer¹, Cesar Fors Nieves², H. Michael Belmont², Peter M. Izmirly², Tibor Becske³,⁴, Paul P. Huang¹

Departments of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, USA, ¹Neurosurgery, ²Division of Rheumatology, ³Radiology, ⁴Neurology, New York University School of Medicine, New York, USA

E-mail: *Christopher S. Graffeo - Graffeo.Christopher@Mayo.edu; Omar Tanweer - Omar.Tanweer@nyumc.org; Cesar Fors Nieves - Cesar.ForsNieves@nyumc.org; H. Michael Belmont - Michael.Belmont@nyumc.org; Peter M. Izmirly - Peter.Izmirly@nyumc.org; Tibor Becske - Tibor.Becske@nyumc.org; Paul P. Huang - Paul.Huang@nyumc.org

*Corresponding author

Received: 05 June 14 Accepted: 02 November 14 Published: 20 January 15

Abstract

Background: Subarachnoid hemorrhage (SAH) due to intracranial aneurysm rupture is a major neurosurgical emergency associated with significant morbidity and mortality. Rapid aneurysm growth is associated with rupture. Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder whose complications can include cerebral vasculitis and vasculopathy. Intracranial aneurysms are not known to occur more frequently in SLE patients than the general population; however, aneurysm growth rates have not been studied in SLE.

Case Description: We present a 43-year-old female with SLE on prednisone, hydroxychloroquine, and azathioprine with moderate disease activity who presented with severe, acute-onset headache and was found to have Hunt and Hess grade II SAH due to rupture of an 8 mm saccular anterior communicating artery (ACoA) aneurysm. The patient developed severe vasospasm, re-ruptured, and was taken for angiography and embolization, which was challenging due to a high degree of vasospasm and arterial stenosis. Review of imaging from less than 2 years prior demonstrated a normal ACoA complex without evidence of an aneurysm.

Conclusion: We review the literature and discuss the risk factors and pathophysiology of rapid aneurysm growth and rupture, as well as the pathologic vascular changes associated with SLE. Although SLE patients do not develop intracranial aneurysm at an increased rate, these changes may predispose them to higher incidence of growth and rupture. This possibility-coupled with increased morbidity and mortality of SAH in SLE-suggests that SAH should be considered in SLE patients presenting with headache, and advocates for more aggressive treatment of SLE patients with unruptured aneurysms.

Key Words: Aneurysm growth, intracranial aneurysms, subarachnoid hemorrhage, systemic lupus erythematosus
INTRODUCTION

Rapid aneurysm growth is reported rarely, and risk factors for aneurysm growth are an area of active debate, with considerable disagreement in the neurosurgical literature. As rapid aneurysm growth is itself a risk factor for rupture, identification of susceptible patients would inform clinical decision-making.

Systemic lupus erythematosus (SLE) is an autoimmune disorder with protean effects on almost every organ system. Central nervous system (CNS) SLE occurs in 24–51% of patients, and although psychosis and seizure are among the diagnostic criteria, cerebrovascular disease is more common. The majority of CNS SLE pathology is atherothromboembolic disease, or secondary extension of parenchymal hemorrhage; however, aneurysmal subarachnoid hemorrhage (SAH) occurs in up to 3.9%.

In this report, we present a patient with SLE who demonstrated rapid growth of an anterior communicating artery (ACoA) aneurysm with rupture, vasospasm, and rebleed.

CASE REPORT

A 43-year-old right-handed African American female with a history of migraines was followed clinically for SLE for 3 years prior to presentation. Her initial diagnosis was based on American College of Rheumatology criteria of: Antinuclear antibodies, dsDNA antibodies, arthritis, and serositis with pericarditis. Recent disease activity was moderate, with arthralgias, occasional fevers, oral ulcers, fatigue, a truncal maculopapular rash, and abnormal C4, dsDNA, and c-reactive protein. Medications included prednisone, hydroxychloroquine, and azathioprine.

The patient presented to the emergency room after a syncopal event with headache, dizziness, and nausea. She had no focal neurologic deficits, improved on migraine medications, and was discharged. Throughout the following week, headaches and fatigue persisted; however, her family reported that these symptoms were comparable to prior SLE flares.

Six days later, the patient was found unresponsive and with one episode of bowel incontinence. She was taken to the emergency department, where she was arousable and oriented. Neurologic examination was significant for moderate expressive aphasia, left-sided hemineglect, flattening of the left nasolabial fold, 4/5 strength in the right upper and lower extremities, and 0/5 strength in the left upper and lower extremities. Hoffman’s and Babinski’s signs were negative, no clonus was observed, and her remaining cranial nerves were intact. Musculoskeletal examination was significant for trace bilateral dorsal hand edema, mild proximal interpharyngeal joint tenderness without synovitis, and a papular, erythematous, scaling rash over her thighs bilaterally.

Computed tomography (CT) and CT angiography demonstrated multiple areas of acute infarct, most prominently in the anterior cerebral artery (ACA) distribution, with minimal interhemispheric SAH and a 8 × 5 mm bilobed saccular aneurysm located at the junction of the left ACA and ACoA. The patient was diagnosed with Hunt and Hess grade II SAH and admitted to the neurosurgical intensive care unit. Initial medical management included oral levetiracetam 500 mg, oral nimodipine 60 mg, and three doses of intravenous methylprednisolone 16 mg/kg. Azathioprine was held, as consideration of alternative immunosuppression with cyclophosphamide or mycophenolate mofetil was deliberated. Since the patient was postbleed day six from initial rupture on admission hospital, the decision was made to withhold endovascular intervention as long as she remained clinically stable and within the vasospasm window.

Five days after admission, the patient became acutely unresponsive, and repeat head CT demonstrated new subarachnoid blood. She was taken emergently for angiography and embolization of the aneurysm. Vasospasm involving the right internal carotid artery (ICA), bilateral ACA, ACoA, supraclinoid left ICA, and right posterior cerebral artery was observed. Of note, catheterization of the A1 segment was difficult, due to severe vasospasm and arterial stenosis.

Postembolization, the patient awoke with dense left hemiparesis, left hemineglect, and severe expressive aphasia. Over several days, the patient’s neglect and aphasia resolved, and she was discharged to acute rehabilitation in stable condition. At follow-up one month after discharge, she demonstrated no signs of aphasia, and was able to converse and interact at her prerupture baseline. She had recovered antigravity strength in her left extremities, and her facial nerve deficit had resolved.

Review of imaging conducted as part of a headache workup 20 months prior to the current admission demonstrated a normal ACoA complex, as per multiple neuroradiologists at our institution. A renal ultrasound was negative for polycystic kidney disease. Additional history did not reveal any other medical conditions or significant risk factors for aneurysm rupture, such as hypertension or smoking. Family history was negative for polycystic kidney disease, connective tissue disorders, SAH, intracranial aneurysms, or sudden deaths suspicious for undiagnosed aneurysm rupture.
DISCUSSION

SAH is a neurosurgical emergency, and 85% of nontraumatic SAH is due to aneurysm rupture.\(^2\) The prognosis among these patients is poor: The overall case fatality rate after rupture is approximately 35%, and although two-thirds of all survivors are able to regain functional independence, half have permanent cognitive impairments, and only a third are able to return to prerupture employment.\(^{27,45}\)

Although prior reports suggested that intracranial aneurysms are more prevalent in SLE patients than the general population, larger and more recent studies have found that the overall incidence is comparable.\(^{18,30,34}\) However, SLE patients bear a worse prognosis, with higher incidence of SAH, increased mortality, and worse Hunt and Hess grades on presentation.\(^{5,18,31,53,54}\) Data on complications including vasospasm or rebleeding are limited, but anecdotal reports suggest that SLE may predispose to adverse outcomes.\(^{17,30,34}\)

Risk factors for rupture have been widely studied, and although some disagreement exists, aneurysm growth is a consistently significant finding.\(^{1,3,20,23,32,35}\) Correspondingly, other studies have investigated independent risk factors for aneurysm growth, which may include location on the ICA, middle cerebral artery, or basilar artery, large aneurysm size, multiple lobes, family history of SAH, active smoking, and female sex.\(^{6,21,24,41,44}\)

Aneurysm formation and growth is influenced by hemodynamic and endothelial changes. Abnormal flow produces local changes in blood pressure and wall shear stress, which lead to endothelial remodeling and consequent changes in aneurysm geometry.\(^{8-10,37,40,42,47-50,55}\) Progressive geometric alteration begets further hemodynamic stress, and the cycle of positive feedback propagates aneurysm growth and rupture. In parallel, inflammation and ischemia induce endothelial remodeling and seed aneurysm growth, via collagen and fibrin deposition within the walls, thinning of the domes, vascular smooth muscle deficiency, fibroblasts and leukocytes infiltration, degradation of matrix proteins, and elevated elastase and collagenase activity.\(^{8,12,19,28,39,51}\)

The greatest risk for rupture occurs during rapid growth, and simulated patient cohorts with variable growth rates better approximate the incidence of SAH than those based on linear models, suggesting that the natural history of aneurysm rupture is characterized by periods of intermittent, unpredictable vulnerability.\(^{10,26,32,55}\)

Presently, a definitive, causal relationship has not been established between SLE and aneurysmal SAH. Although SLE is frequently associated with cerebrovascular pathology, small vessels are affected, rather than the Circle of Willis.\(^{40}\) Notwithstanding, histopathologic studies have identified inflammation, vasculitis, and fibrinoid necrosis within ruptured aneurysm walls from SLE patients.\(^{4,29,30,36,45,46}\) Other investigations have found large-vessel damage from immune complex deposition, accelerated atherosclerosis, and predisposition to coagulopathy.\(^{11,16,46}\) Taken together, these findings suggest
a role for autoimmune damage underlying rupture pathophysiology in SLE patients.

Approaching the link between SLE and SAH clinically, a study incorporating the Systemic Lupus International Collaborating Clinics (SLICC) damage score—a metric for quantifying damage from SLE or its treatment—observed scores ≥2 in 80% of ruptures, suggesting that chronic damage contributes to vascular weakness. Other studies observed that 60–70% of SAH occurred >5 years after SLE diagnosis, suggesting a dose–response relationship. However, other reports observed that SLE disease activity is equally distributed at high and low levels following rupture, suggesting that aneurysm formation, growth, and rupture may be independent of SLE disease activity. Notwithstanding, if a causative relationship exists between the entities, the crucial pathophysiology is more to occur prior to rupture rather than immediately following, a mechanism that has not yet been evaluated.

The present case highlights the challenges of balancing immunosuppression against control of autoimmunity. CNS SLE indicates aggressive immunosuppression, yet the relationship between disease activity and symptoms is clear in those patients, for whom the benefits clearly outweigh the risks. In contrast, given the lack of evidence linking SLE disease activity to SAH, and the likelihood that patients with aneurysm rupture will require neurosurgical intervention, maintaining SLE immunosuppressive following rupture pose a substantial risk of infection, and no defined benefit in terms of neurovascular outcome. This conflict stresses the need for an understanding of the relationship between SLE vascular pathologies and SAH complications.

Careful consideration should be given to the role of endovascular intervention in these patients. Given the possibility that SLE may predispose to growth and rupture, early intervention may be more beneficial than in the general population. Among SLE patients who rupture, it may be possible to reduce the risk of rebled by treating emergently, although no current evidence supports or refutes this theory. However, SLE may also predispose to vessel stenosis, potentially limiting the role for angioplasty and superselective drug infusions. In the present case, we elected to attempt slow passage of the microcatheter through the stenotic segment first, with a plan to pursue vasopasm treatment with verapamil or balloon angioplasty if that proved technically unfeasible. Based on our experience, we anticipate that endovascular therapy for ruptured aneurysms in SLE patients will demand highly individual tailoring.

**CONCLUSION**

This is the first reported case of rapid aneurysm growth and rupture in a patient with SLE to the authors' knowledge, and this review highlights major deficiencies in the current understanding of the relationship between SLE and aneurysm biology. Although aneurysmal SAH is rare in SLE, it should be considered in patients presenting with headache. Further, when aneurysms are identified in patients with SLE, they should be followed closely, and considered for more aggressive treatment with endovascular embolization or open surgical clipping—especially if growth is observed.

**REFERENCES**

1. Unruptured intracranial aneurysms—risk of rupture and risks of surgical intervention. International Study of Unruptured Intracranial Aneurysm Investigators. N Engl J Med 1998;339:1725-33.
2. Al-Khindi T, Macdonald RL, Schweizer TA. Cognitive and functional outcome after aneurysmal subarachnoid hemorrhage. Stroke 2010;41:e539-46.
3. Alcocock JM, Canham PB. Angiographic study of the growth of intracranial aneurysms. J Neurol Neurosurg Psychiatry 1976;45:617-21.
4. Asai A, Matsuzumi M, Kohno T, Fujimaki T, Takakura K. Multiple saccular cerebral aneurysms associated with systemic lupus erythematosus—case report. Neurol Med Chir (Tokyo) 1989;29:245-7.
5. Baizabal Carvallo JF, Cantu Brito C, Esanol B, Garcia Ramos GS. Subarachnoid hemorrhage as a complication of systemic lupus erythematosus. Cerebrovasc Dis 2007;24:301-4.
6. Chen WP, Okudera T, Hatazawa J, Yusu N, Miura Y, Onodera H, et al. Natural history of unruptured aneurysm: A long-term follow-up angiographic study. AJNR Am J Neuroradiol 2000;21:161-77.
7. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012;43:1711-37.
8. Crompton MR. Mechanism of growth and rupture in cerebral berry aneurysms. Br Med J 1966;1:1138-42.
9. Dietrich W, Reinprecht A, Gruber A, Czech T. De novo formation and rupture of an azgos pericallosal artery aneurysm. Case report. J Neurol Neurosurg Psychiatry 2000;69:1062-4.
10. Doenitz C, Schebesch KM, Zoepfel R, Brawanski A. A mechanism for the rapid development of intracranial aneurysms: A case study. Neurosurgery 2010;67:1213-21.
11. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: A review of neuropathologic findings in 57 cases, 1955-1977. Semin Arthritis Rheum 1979;8:212-21.
12. Gueant R, Pillay K, Rodriguez y Baena R, Tartara F, Messina AL, Tancioni F, Schiavo R, et al. Metalloproteases and intracranial vascular lesions. Neurol Res 1999;21:385-90.
13. Gladman DD, Goldsmith CH, Urowitz MB, Bacon PA, Bremner M, Canfield M, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 2000;27:373-6.
14. Gomis P, Grafeiaux JP, Sercombe R, Hetelier D, Scherpereel B, Rousseaux P. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurol Neurosurg Psychiatry 2010;81:681-8.
15. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2011;7:338-47.
16. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992;19:732-41.
17. Hashimoto N, Handa H, Takeda W. Ruptured cerebral aneurysms in patients with systemic lupus erythematosus. Surg Neurol 1986;26:512-6.
18. Hinchee JA, Sla CA. Cerebrovascular complications of rheumatic disease. Rheum Dis Clin North Am 1997;23:293-316.
19. Ingawa T, Hirano A. Autopsy study of unruptured incidental intracranial aneurysms. Surg Neurol 1990;34:361-5.
20. Juvela S. Natural history of unruptured intracranial aneurysms: Risks for aneurysm formation, growth, and rupture. Acta Neurochir Suppl 2002;82:27-30.
21. Juvela S, Porras M, Heiskanen O. Natural history of unruptured intracranial aneurysms: A long-term follow-up study. J Neurosurg 1993;79:174-82.
22. Juvela S, Porras M, Poussa K. Natural history of unruptured intracranial aneurysms: Probability of and risk factors for aneurysm rupture. J Neurosurg 2008;108:1052-60.
23. Juvela S, Poussa K, Lehto H, Porras M. Natural history of unruptured intracranial aneurysms: A long-term follow-up study. Stroke 2013;44:2414-21.
24. Juvela S, Poussa K, Porras M. Factors affecting formation and growth of intracranial aneurysms: A long-term follow-up study. Stroke 2001;32:485-91.
25. Kael AT, Shestov M, Lee BC, Lockshin MD. The diversity of neurologic events in systemic lupus erythematosus. Prospective clinical and computed tomographic classification of 82 events in 71 patients. Arch Neurol 1986;43:273-6.
26. Kailasnath P, Chaloupka JC, Dickey PS. A multiplicative statistical model predicts the size distribution of unruptured intracranial aneurysms. Neuror Res 1998;20:421-6.
27. Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: Surgical results. J Neurosurg 1990;73:37-47.
28. Katoaka K, Taneda M, Asai T, Yamada Y. Difference in nature of ruptured and unruptured cerebral aneurysms. Lancet 2000;355:203.
29. Kawamata T, Kagawa M, Kubo O, Takeshita M, Ujike H, Sato K, et al. [Clinicopathological studies of three cases of cerebral aneurysms associated with systemic lupus erythematosus]. No Shinkei Geka 1991;19:633-9.
30. Kelley RE, Stokes N, Reyes P, Harik SI. Cerebral transmural angiitis and ruptured aneurysm: A complication of systemic lupus erythematosus. Arch Neurol 1980;37:526-7.
31. Kitagawa Y, Gotoh F, Koto A, Okayasu H. Stroke in systemic lupus erythematosus. Stroke 1990;21:1533-47.
32. Koffljberg H, Buskens E, Algra A, Wermers M, Rinkel GJ. Growth rates of intracranial aneurysms: Exploring constancy. J Neurosurg 2008;109:176-85.
33. Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med 2005;118:141S.
34. Lalani TA, Kanne JP, Hazfield GA, Chen P. Imaging findings in systemic lupus erythematosus. Radiographics 2004;24:1069-86.
35. Lanzino G, Brown RD Jr. Natural history of unruptured intracranial aneurysms. J Neurosurg 2012;117:50-1.
36. Manabe H, Oh, Kim BG, Sekiya T, Suzuki S. Three cases of aneurysmal subarachnoid hemorrhage combined with SLE. Tohoku No Kekkann Shogai Konwakai 1993;67-72.
37. Mathews MG, Castillo M. Development of de novo intracranial aneurysm in three months: Case report and literature review. AJNR Am J Neuroradiol 2003;24:709-10.
38. Matsubara S, Hadeishi H, Suzuki A, Yasui N, Nishimura H. Incidence and risk factors for the growth of unruptured cerebral aneurysms: Observation using serial computerized tomography angiography. J Neurosurg 2004;101:908-14.
39. Meng H, Tutino VM, Xiang J, Siddiqui A. High WSS or Low WSS? Complex interactions of hemodynamics with intracranial aneurysm initiation, growth, and rupture: Toward a unifying hypothesis. AJNR Am J Neuroradiol 2014;35:1254-62.
40. Mimori A, Suzuki T, Hashimoto M, Nara H, Yoshio T, Masuyama JI, et al. Subarachnoid hemorrhage and systemic lupus erythematosus. Lupus 2000;9:521-6.
41. Miyazawa N, Akiyama I, Yamagata Z. Risk factors for growth of unruptured intracranial aneurysms: Follow-up study by serial 0.5-T magnetic resonance angiography. Neurosurgery 2006;58:1047-53.
42. Okazaki T, Nishi T, Yamashiro S, Koga K, Nagahiro S, Fujioka S. De novo formation and rupture of an intracranial aneurysm 10 months after normal findings on conventional magnetic resonance angiography in a patient with no history of intracranial lesions: Case report. Neurol Med Chir (Tokyo) 2010;50:309-12.
43. Owada T, Takahashi K, Kita Y. Subarachnoid hemorrhage in systemic lupus erythematosus in Japan: Two case reports and a review of the literature. Mod Rheumatol 2009;19:573-80.
44. Phan TG, Huston J 3rd, Brown RD Jr, Wiebers DO, Piepras DG. Intracranial saccular aneurysm enlargement determined using serial magnetic resonance angiography. J Neurosurg 2002;97:1023-8.
45. Rinkel GJ, Algra A. Long-term outcomes of patients with aneurysmal subarachnoid haemorrhage. Lancet Neurol 2011;10:349-56.
46. Sakaki T, Morimoto T, Utsumi S. Cerebral transmural angiitis and ruptured cerebral aneurysms in patients with systemic lupus erythematosus. Neurocirugia (Stuttgart) 1990;33:122-5.
47. Schebesch KM, Doenitz C, Zoepel R, Finkenzeller T, Brawanski AT. Recurrent subarachnoid hemorrhage caused by a de novo basilar tip aneurysm developing within 8 weeks after clipping of a ruptured anterior communicating artery aneurysm: Case report. Neurosurgery 2008;62:241-50.
48. Sheffield EA, Weller RO. Age changes at cerebral artery bifurcations and the pathogenesis of berry aneurysms. J Neurol Sci 1980;46:341-52.
49. Shojima M, Morita A, Kimura T, Oshima M, Kin T, Saito N. Computational fluid dynamic simulation of a giant basilar tip aneurysm with eventual rupture after hunterian ligation. World Neurosurg 2014;82:535.e5-9.
50. Shojima M, Oshima M, Takagi K, Torii R, Hayakawa M, Kazada K, et al. Magnitude and role of wall shear stress on cerebral aneurysms: Computational fluid dynamic study of 20 middle cerebral artery aneurysms. Stroke 2004;35:2500-5.
51. Stehbens WE. Pathology of the cerebral blood vessels. Saint Louis: C.V. Mosby; 1972.
52. Wallace DJ, Hahn B, Dubois EL. Dubois’ lupus erythematosus and related syndromes. 8th ed. Philadelphia, PA: Elsevier/Saunders; 2013.
53. Weir B. Unruptured intracranial aneurysms: A review. J Neurosurg 2002;96:3-42.
54. Yamada S, Koizumi A, Iso H, Wada Y, Watanabe Y, Date C, et al. Risk factors for fatal subarachnoid hemorrhage: The Japan Collaborative Cohort Study. Stroke 2003;34:2781-7.
55. Yasuhara T, Tamiya T, Sugiu K, Inoue S, Ohmoto T. De novo formation and rupture of an aneurysm. Case report. J Neurosurg 2002;97:697-700.

http://www.surgicalneurologyint.com/content/6/1/9